Drug – bio-affecting and body treating compositions – Nonspecific immunoeffector – per se ; or nonspecific... – Synthetic polymer or copolymer
Patent
1995-04-11
1996-09-10
Housel, James C.
Drug, bio-affecting and body treating compositions
Nonspecific immunoeffector, per se ; or nonspecific...
Synthetic polymer or copolymer
4242781, 4242831, 4242791, 514723, 5147723, A61K 4500, A61K 4730
Patent
active
055543723
ABSTRACT:
The present invention comprises adjuvants which, when admixed with an antigen and administered into a human or animal, will induce a more intense immune response to the antigen than when the antigen is administered alone. In many cases, the adjuvant that is described as the present invention will increase overall titer of antibodies of a specific isotype which are specific for the antigen. For example, in mice, when the adjuvant of the present invention is admixed with a conventional antigen, the isotype that is induced in the mouse is changed from a predominantly IgG1 isotype to the more protective IgG2 isotype and, in some cases, IgG3 isotype. Thus, by practicing the present invention, one can improve the overall protective effect of conventional vaccines.
REFERENCES:
patent: 2674619 (1954-04-01), Lundsted
patent: 2979528 (1961-04-01), Lundsted
patent: 3022335 (1962-02-01), Lundsted
patent: 3036118 (1962-05-01), Jackson et al.
patent: 3867521 (1975-02-01), Miskel et al.
patent: 3869546 (1975-03-01), Lund
patent: 3869549 (1975-03-01), Geller
patent: 4101536 (1978-07-01), Yamamura et al.
patent: 4158052 (1979-06-01), Audibert et al.
patent: 4185089 (1980-06-01), Derrien et al.
patent: 4314998 (1982-02-01), Yamamura et al.
patent: 4323559 (1982-04-01), Audibert et al.
patent: 4323560 (1982-04-01), Baschang et al.
patent: 4369178 (1983-01-01), Yamamura et al.
patent: 4372945 (1983-02-01), Likhite
patent: 4382080 (1983-05-01), Shiba et al.
patent: 4400376 (1983-08-01), Sanderson
patent: 4406889 (1983-09-01), Hartmann et al.
patent: 4409209 (1983-10-01), Baschang et al.
patent: 4423038 (1983-12-01), Baschang et al.
patent: 4427659 (1984-01-01), Le Francier et al.
patent: 4461761 (1984-07-01), Le Francier et al.
patent: 4478823 (1984-10-01), Sanderson
patent: 4503036 (1985-05-01), Girardon et al.
patent: 4606918 (1986-08-01), Allison et al.
patent: 4609546 (1986-09-01), Hiratani
patent: 4770874 (1988-09-01), Allison et al.
patent: 4803070 (1989-02-01), Cantrell et al.
patent: 4806352 (1989-02-01), Cantrell
patent: 4866034 (1989-09-01), Ribi
patent: 4912094 (1990-03-01), Myers et al.
Abstract: Biosis Accession No. 64008712, Mancino, D. et al., "Adjuvant Effect of Amorphous Silica on the Immune Response to Various Antigens in Guinea-Pigs," Int. Arch. Allergy Appl. Immunol., vol. 53, No. 2, pp. 97-103 (1977).
Morrison et al., "Adjuvant-free immunological manipulation of livestock", Res. Vet. Sci., vol. 37, pp. 108-113 (1984).
Stevens, "A synthetic peptide vaccine against human chlorionic gonadotropin", Vaccines 86, pp. 39-44 (1986).
Pike et al., "A reappraisal of `T-independent` antigens. I. Effect of lymphokines on the response of single adult hapten-specific B lymphocytes", J. Immunol., vol. 132, No. 4, pp. 1687-1695 (1984).
Feldmann, "Induction of immunity and tolerance in vitro by hapten protein conjugates. II. Carrier independence of the response to dinitrophenylated polymerized flagellin", Eur. J. Immunol., vol. 2, pp. 130-137 (1972).
Majarian et al., "Expression of heterologous epitopes as recombinant flagella on the surface of attenuated Salmonella", Vaccines 89, pp. 277-281 (1989).
Netwon et al., "Immune response to cholera toxin epitope inserted in Salmonella flagellin", Science, vol. 244, pp. 70-72 (1989).
Nossal et al., "Antigens in immunity. II. Immunogenic properties of flagella, polymerized flagellin and flagellin in the primary response", Aust. J. Exp. Biol. Med. Sci., vol. 42, pp. 283-294 (1964).
Kobayashi et al., "Purification and chemical properties of flagellin", Arch. Biochem. Biophys., vol. 84, pp. 342-362 (1959).
Feldmann et al., "The relationship between antigenic structure and the requirement for thymus-derived cells in the immune response", J. Exp. Med., vol. 134, pp. 103-119 (1971).
Lee et al., "Communications: Decline and spontaneous recovery of the monoclonal response to phosphorylcholine during repeated immunization", J. Immunol., vol. 113, No. 5, pp. 1644-1646 (1974).
Rietschel et al., "Bacterial endotoxins: Relationships between chemical structure and biological activity", Immunological Adjuvants & Vaccines, ed. Gregoriadis et al., Series A: Life Sciences vol. 179, pp. 61-74 ().
Galanos et al., "Biological activities and immunological properties of lipid A", Microbiology, pp. 269-276 (1977).
Haslberger et al., "Immunopharmacology of lipopolysaccharides (endotoxins) from gram-negative bacteria", Triangle, vol. 26, No. 1, pp. 33-49 (1987).
Louis et al., "Lipopolysaccharides: From immunostimulation to autoimmunity", Springer Semin. Immunopathol., vol. 2, pp. 215-228 (1979).
Qureshi, et al., "Purification and structural determination of nontoxic lipid A obtained from the lipopolysaccharide of Salmonella Typhimurium", J. Biol. Chem., vol. 257, No. 19, pp. 11808-11815 (1982).
Kotani et al., "Immunobiologically active lipid A analogs synthesized according to a revised structural model of natural lipid A", Infect. Immun., vol. 45, No. 1, pp. 293-296 (1984).
Ribi et al., "Lipid A and immunotherapy", Rev. Infect. Dis., vol. 6, No. 4, pp. 567-572 (1984).
Hadjipetrou-Kourounakis et al., "Adjuvants influence the immunoglobin subclass distribution of immune responses in vivo", Scand. J. Immunol., vol. 19, pp. 219-225 (1984).
Munford et al., "Detoxification of bacterial lipopolysaccharides (endotoxins) by a human neutrophil enzyme", Science, vol. 234, pp. 203-205 (1986).
Kanegasaki et al., "Structure-activity relationship of lipid A: Comparison of biological activities of natural and synthetic lipid A's with different fatty acid compositions", J. Biochem., vol. 99, pp. 1203-1210 (1986).
Hunter et al., "The adjuvant activity of nonionic block polymer surfactants. III. Characterization of selected biologically active surfaces", Scand. J. Immunol., vol. 23, pp. 287-300 (1986).
Hunter et al., "The adjuvant activity of nonionic block polymer surfactants. I. The role of hydrophile-lipophile balance", J. Immunol., vol. 127, No. 3, pp. 1244-1250 (1981).
Snippe et al., "Adjuvant effect of nonionic block polymer surfactants in humoral and cellular immunity", Int. Archs. Allery Appl. Immun., vol. 65, pp. 390-398 (1981).
Hunter et al., "Nonionic block copolymer surfactants as immunological adjuvants: Mechanisms of action and novel formulations", Immunological Adjuvants & Vaccines, ed. Gregoriadis et al., Plenum Publishing Corp., pp. 133-144 (1989).
W. R. Clark, "The Properties and Fine Structure of Immunoglobulins", The Experimental Foundations of Modern Immunology, 3rd ed., John Wiley & Sons, pp. 62-74.
Hoffman et al., "Naturally acquired antibodies to sporozoites do not prevent malaria: Vaccine development implications", Science, vol. 237, pp. 639-642 (1987).
Egan et al., "Efficacy of murine malaria sporozoite vaccines: Implications for human vaccine development", Science, vol. 236, pp. 453-456 (1987).
Good et al., "Construction of synthetic immunogen: Use of new T-helper epitope on malaria circumsporozite protein", Science, vol. 235, pp. 1059-1062 (1987).
Hoffman et al., "Immunity to malaria and naturally acquired antibodies to the circumsporozoite protein of plasmodium falciparum", N. Engl. J. Med., vol. 315, No. 10, pp. 601-606 (1986).
Hunter, R. L., et al., "The Adjuvant Activity of Nonionic Block Polymer Surfactants II. Antibody Formulation and Inflammation Related to the Structure of Triblock and Octablock Copolymers", J. Immunol., vol. 133, pp. 3167-3175 (1984).
Schmolka, J. R., "A Review of Block Polymer Surfactants", J. Am. Oil Chemists' Soc., 54:110-116 (1977).
Block and Graft Copolymerization, vol. 2, edited by R. J. Ceresa, John Wiley & Sons, New York (1976).
Raetz, C. R. H., "Structure and Biosynthesis of Lipid A in Escherichia coli", Cellular and Molecular Biology, vol. 1, Neidhardt, F. C. Editor, American Society for Microbiology.
Liang, X, et al., "Oral Administration of Cholera Toxin-Sedai Virus Conjugate Potentiates Gut and Respiratory Immunity Against Sendai Virus", J. Immunol., vol. 141, No. 5, pp. 1495-1501 (1988).
Wechsler, D. S., et al., "Heat labile IgG2a antibodies affect cure of Trypanosoma muculi infection in C57BL/6 mice", J. Immunol. vol. 137, pp.
Emory University
Housel James C.
Shaver Jennifer
LandOfFree
Methods and vaccines comprising surface-active copolymers does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and vaccines comprising surface-active copolymers, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and vaccines comprising surface-active copolymers will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1318763